Search results
Email: ir@bmrn.com. Tel: + 1 (415) 455-7558. BioMarin Pharmaceutical Australia is a leader in developing and commercialising innovative biopharmaceuticals for rare diseases driven by genetic causes.
Jun 29, 2023 · The U.S. Food and Drug Administration on Thursday approved BioMarin Pharmaceutical's gene therapy for severe hemophilia A, the company said, giving patients with the inherited bleeding disorder an ...
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical ...
Jun 29, 2023 · Jun 29, 2023 ROCTAVIAN is a One-Time, Single-Dose Treatment Available for Adults with Severe Hemophilia A to Control Bleeds ROCTAVIAN's Approval was Based on Durability, Efficacy and Safety Results from the Largest and Longest Phase 3 Study for a Gene Therapy for Hemophilia Majority of Patients Continued to Respond to ROCTAVIAN Treatment over 3 Years Conference Call and Webcast to be Held at 4 ...
Feb 8, 2024 · At Biomarin Pharmaceutical Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.
View the latest BioMarin Pharmaceutical Inc. (BMRN) stock price, news, historical charts, analyst ratings and financial information from WSJ.
BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. The company operates its business through one segment, the ...
